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Abstract
BACKGROUNDANDAIMS: The standard palliative chemotherapy for pancreatic ductal adenocarcinoma (PDAC) is gemcitabine-based
chemotherapy; however, PDAC still presents amajor therapeutic challenge. The aims of this study were to investigate the expression
pattern of genes involved in gemcitabine sensitivity in resected PDAC tissues and to determine correlations of gene expression
with treatment outcome. MATERIALS AND METHODS: We obtained formalin-fixed paraffin-embedded (FFPE) tissue samples from
70 patients with PDAC. Of the 70 patients, 40 received gemcitabine-based adjuvant chemotherapy (AC). We measured hENT1, dCK,
CDA, RRM1, and RRM2messenger RNA (mRNA) levels by quantitative real-time reverse transcription–polymerase chain reaction and
determined the combined score (GEM score), based on the expression levels of hENT1, dCK, RRM1, and RRM2, to investigate
the association with survival time. By determining the expression levels of these genes in endoscopic ultrasound-guided fine needle
aspiration (EUS-FNA) cytologic specimens, we investigated the feasibility of individualized chemotherapy. RESULTS: High dCK
(P = .0067), low RRM2 (P = .003), and high GEM score (P = .0003) groups had a significantly longer disease-free survival in the
gemcitabine-treated group. A low GEM score (<2) was an independent predictive marker for poor outcome to gemcitabine-based
AC as shown by multivariate analysis (P = .0081). Altered expression levels of these genes were distinguishable in microdissected
neoplastic cells from EUS-FNA cytologic specimens. CONCLUSIONS:Quantitative analyses of hENT1, dCK, RRM1, and RRM2mRNA
levels using FFPE tissue samples andmicrodissected neoplastic cells from EUS-FNA cytologic specimensmay be useful in predicting
the gemcitabine sensitivity of patients with PDAC.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal
and aggressive human malignancies, being the fourth leading cause of
tumor-related deaths in the industrialized world [1,2]. Most patients
with PDAC have poor outcomes because of the aggressive biology of the
tumor and the difficulties of early diagnosis because of a lack of early
disease-specific signs and symptoms. Only 10% to 20% of patients with
PDAC are candidates for curative resection [3], and even if the curative
resection is performed, the postoperative 5-year survival rate is only 15%
to 25% because of a high recurrence rate [4,5]. Although two recent
randomized clinical phase 3 trials of adjuvant chemotherapy (AC) for
PDAC showed significant increases in overall survival (OS) and disease-
free survival (DFS) [6,7], there remain a substantial subset of cases in
which AC efficacy is limited and insufficient. Recent studies have revealed
that altered gene expression can at least partly explain responses and tox-
icity of cytotoxic agents [8]. To improve the prognosis of patients with
PDAC, a helpful strategy would be to select subjects who are likely to
respond to treatment based on gene expression profiles of the individ-
ual’s own cancer tissues.
Gemcitabine (difluorodeoxycytidine; dFdC) is a deoxycytidine an-
alog that has broad antitumor activity in various solid tumors, includ-
ing pancreatic cancer [7] and non–small cell lung cancer (NSCLC) [9].
The drug is a prodrug that requires cellular uptake and intracellular
phosphorylation to produce active diphosphate (dFdCDP) and tri-
phosphate (dFdCTP). These phosphorylated forms function by in-
hibiting ribonucleotide reductase (RR) and DNA synthesis [10].
Gemcitabine is transported into cells predominantly by human equili-
brative nucleoside transporter 1 (hENT1) [11]. A deficiency in hENT1
activity conferred high-level resistance to the toxicity of gemcitabine
[12], and patients with PDAC that have detectable hENT1 or high
hENT1 gene expression have significantly prolonged survival after gem-
citabine chemotherapy [13,14]. After cellular entry, gemcitabine must
be phosphorylated by deoxycytidine kinase (dCK), which is a rate-
limiting step. We previously demonstrated that down-regulation of
dCK specifically enhanced acquired resistance to gemcitabine in pan-
creatic cancer cells [15], whereas transfection of wild-type dCK re-
stored sensitivity to the drug [16]. Conversely, active metabolites of
gemcitabine are reduced by 5′-nucleotidase (5′-NT), and gemcitabine
itself is inactivated by cytidine deaminase (CDA). High levels of these
catabolic enzymes are associated with resistance to the drug [17,18].
dFdCTP inhibits DNA synthesis by being incorporated into the
DNA strand, but in addition, dFdCDP potently inhibits RR, resulting
in a decrease of competing deoxyribonucleotide pools necessary for
DNA synthesis [19]. RR is a dimeric enzyme composed of regulatory
subunit M1 and catalytic subunit M2. Recurrent PDAC patients with
high levels of RRM1 expression had poor survival rates after gemcitabine
treatment [20], and NSCLC patients with low levels of RRM1 expres-
sion significantly benefited from gemcitabine/cisplatin neoadjuvant che-
motherapy [21]. Moreover, RRM2 gene silencing by RNA interference
is an effective therapeutic adjunct to gemcitabine treatment [22]. These
data suggest that the genes encoding proteins involved in the transport
and metabolism of gemcitabine and in the metabolism of targets can be
potential candidates to predict sensitivity to gemcitabine.
To develop individualized chemotherapy, the characterization of
genes associated with tumor sensitivity or resistance to antitumor agents
using cancer tissues from individuals plays a critical role in the selection
of preferable treatments. In the current study, we investigated the corre-
lation between the expression of genes involved in cellular uptake and
metabolism of gemcitabine and the treatment outcome of patients with
PDAC who underwent gemcitabine-based AC or no AC. Furthermore,
to investigate the feasibility of individualized chemotherapy for patients
with PDAC, even when the tumor is unresectable, we quantified the
expression of genes in cytologic specimens obtained from endoscopic
ultrasound-guided fine needle aspiration (EUS-FNA).
Materials and Methods
Cell Lines and Establishment of Gemcitabine-Resistant Cells
We used two pancreatic cancer cell lines, SUIT-2 (generously pro-
vided by Dr H. Iguchi, National Shikoku Cancer Center, Matsuyama,
Japan) and Capan-1 (American Type Culture Collection, Manassas, VA).
Gemcitabine-resistant Capan-1-GR and SUIT-2-GR cells were generated
by exposing to gradually increasing concentrations of gemcitabine as
described previously [15]. Cells were maintained as described previ-
ously [23].
Propidium Iodide Assay
To calculate the 50% inhibitory concentration (IC50) of each cell
line when exposed to gemcitabine, cells were seeded in 24-well plates
(Becton Dickinson Labware, Bedford, MA) at a density of 2 × 104 per
well, using cell numbers previously counted using a particle distribu-
tion analyzer CDA 500 (Sysmex, Kobe, Japan). Several different con-
centrations of gemcitabine (Wako, Osaka, Japan) were added 24 hours
after seeding. Cell populations were evaluated by measuring the fluo-
rescence intensity of propidium iodide after a further incubation for
72 hours, as described previously [24].
Patients and Pancreatic Tissues
Our study subjects consisted of 70 patients including 40 patients
who received gemcitabine-based AC (GEM group) and 30 patients
who received no AC (non-AC group) after pancreatic resection for
PDAC at the Department of Surgery and Oncology, Kyushu Univer-
sity Hospital (Fukuoka, Japan) from 1992 to 2007. Although there
were 48 patients who received gemcitabine-based AC, eight patients
were excluded because they did not receive adequate AC. The GEM
group patients (n = 40) received gemcitabine-based AC, consisting of
two ormore cycles of 1000mg/m2 per day of gemcitabine on days 1, 8,
and 15 every 28 days, or three ormore cycles of 1000mg/m2 per day of
gemcitabine on days 1 and 8 every 21 days. The patients were 42 men
and 28 women with a median age of 65 years (range, 36-86 years). We
recommended that patients have follow-up visits every 3 months for
2 years, then visits every 6 months for 3 years, and then annual visits.
DFS was defined as the time from the date of pancreatic resection to
the date of local or distant recurrence. The date of recurrence was de-
fined as the date of the first subjective symptom heralding relapse, or
the date of documentation of recurrent disease, independent of site, as
assessed by diagnostic imaging techniques (whichever occurred first).
Data for patients without recurrence were censored at the time of the
last follow-up visit. OS was measured from the date of pancreatic re-
section to the date of death. Fifty-seven patients died during follow-up,
and the other patients were censored at the time of the last follow-up visit.
Data were analyzed in December 2009, and follow-up data from all cases
were available. The median observation time for DFS was 8.0 months
(range, 0.5-114 months) and that for OS was 15.7 months (range,
0.5-114 months). The clinicopathologic characteristics of the tumors
collected from a total of 70 patients are noted in Table W1.
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All resected specimens were fixed in formalin and embedded in par-
affin for pathologic diagnosis. All tissues adjacent to the specimens
were evaluated histologically according to the criteria of the World
Health Organization. Two pathologists were in agreement with regard
to the pathologic features of all cases and both confirmed the diag-
noses. The stage of tumors was assessed according to UICC (Union
Internationale Contre le Cancer and the American Joint Committee
on Cancer) guidelines [25]. The study was approved by the ethics com-
mittee of Kyushu University and conducted according to the Ethical
Guidelines forHumanGenome/GeneResearch enacted by the Japanese
Government and the Helsinki Declaration.
Cytologic Specimens
Cytologic specimens were obtained at the time of cytologic exam-
ination and diagnosis from the pathologic laboratory of Kyushu Uni-
versity Hospital (Fukuoka, Japan). In brief, cytologic specimens were
divided into whole cell pellets (WCPs) and into three or more smears
as soon as possible after retrieval. Smears were processed in three differ-
ent ways as described previously [26]. Two smears were mounted on
standard glass slides for Hemacolor staining (Merck KGaA, Darmstadt,
Germany) and Papanicolaou staining and were then used for rapid cy-
tologic diagnosis and strict cytologic diagnosis, respectively. These two
smears were examined histologically by cytopathologists, and diagnosis
was confirmed according to Papanicolaou classification. The third smear
of each specimen was mounted on membrane slides (P.A.L.M. Micro-
laser Technologies, Bernried, Germany) for laser capture microdissec-
tion. These smears were stained in 1%Toluidine blue staining solution
or by Hemacolor staining. Fifteen cytologic specimens were obtained
from patients at the Kyushu University Hospital (Fukuoka, Japan)
who underwent endoscopic ultrasound-guided fine needle aspiration
(EUS-FNA) cytology and whose lesions were cytopathologically diag-
nosed as PDAC.
Isolation of RNA
Total RNA was extracted from cultured cells using a High-Pure
RNA Isolation Kit (RocheDiagnostics,Mannheim, Germany) accord-
ing to the manufacturer’s instructions. Total RNA was isolated from
formalin-fixed paraffin-embedded (FFPE) tissue samples using the
RNeasy FFPE kit (Qiagen, Tokyo, Japan) with modification of the
manufacturer’s instructions after macrodissection based on a review
of representative hematoxylin and eosin–stained slides as described
previously [27]. Total RNAwas extracted from cells isolated by micro-
dissection according to the standard acid guanidinium thiocyanate-
phenol-chloroform (AGPC) protocol [28], with or without glycogen
(Funakoshi, Tokyo, Japan).
Quantitative Real-time Reverse Transcription–Polymerase
Chain Reaction
Quantitative real-time reverse transcription–polymerase chain re-
action (qRT-PCR) was performed using a Chromo4 Real-time PCR
Detection System (BIO-LAD Laboratories, Hercules, CA) and a
LightCycler 480 II Real-time PCR System (Roche Diagnostics) for
40 cycles for 15 seconds at 95°C and 1 minute at 55°C with a Quanti-
Tect SYBR Green Reverse Transcription–PCR kit (Qiagen) according
to the manufacturer’s instructions [29]. We designed specific primers
(Table 1) and performed BLASTN searches to confirm the primer spec-
ificities. The level of each mRNA was calculated from a standard curve
constructed with total RNA from Capan-1, a human pancreatic cancer
cell line. The level of each mRNA was normalized to that of β-actin.
The PCR product sizes of each primer pair are small, which allowed
accurate and sensitive qRT-PCR despite the fragmented RNA ex-
tracted from FFPE tissue specimens [30,31].
Statistical Analyses
Statistical analyses and graph presentations were made using JMP
7.01 software (SAS Institute, Cary, NC). Values are expressed as the
mean ± SD. Comparisons between two groups were performed by
Student’s t test. Messenger RNA (mRNA) were split into high- and
low-level groups using recursive descent partition analysis of all patients
(n = 70) or the GEM group (n = 40), as described by Hoffmann et al.
[32]. Categorical variables were compared using the χ 2 test (Fisher exact
probability test). Survival curves were constructed using the Kaplan-
Meier product-limit method and were compared by the log-rank test.
To evaluate independent predictive or prognostic factors associated with
survival time, multivariate Cox proportional hazards regression analysis
was used. Statistical significance was defined as P < .05.
Results
Altered Expression of Genes Encoding Proteins Associated with
Gemcitabine Sensitivity in Gemcitabine-Resistant Pancreatic
Cancer Cell Lines
Gemcitabine-resistant SUIT-2 (SUIT-2-GR) and Capan-1 (Capan-
1-GR) cells were generated by exposure to gradually increasing con-
centrations of gemcitabine. The IC50 values for gemcitabine of the
gemcitabine-resistant cells were significantly higher than those of pa-
rental cells, respectively (Table 2). We also quantified the expression
levels of genes involved in gemcitabine uptake andmetabolism (Figure 1,
A-E ). SUIT-2-GR cells expressed significantly lower levels of hENT1
and dCK and significantly higher levels of RRM1 and CDA compared
with parental cells. Capan-1-GR cells expressed significantly lower levels
of dCK and significantly higher levels of CDA compared with parental
cells, although the expression levels of CDA were lower than those of
SUIT-2 cells. Therefore, alterations of hENT1, dCK, RRM1, and
CDA expression were associated with the development of gemcitabine
resistance in SUIT-2 cells, whereas only two genes, dCK and CDA, were
associated in Capan-1 cells. These data suggest that there are different
patterns of gene expression that can develop gemcitabine resistance, and
evaluation of several genes is needed to predict gemcitabine sensitivity.
Univariate and Multivariate Analyses of Each mRNA Level
Associated with Gemcitabine Sensitivity and Survival Time
To investigate predictive markers of sensitivity to gemcitabine-based
AC in PDAC patients, we quantified hENT1, dCK, RRM1, RRM2,
Table 1. Primer Sequences and Product Sizes.
Primer Forward Reverse Product Size (bp)
Sequence 5′-3′ Sequence 5′-3′
hENT1 gcaaaggagaggagccaagag gggctgagagttggagactg 65
dCK gctgcagggaagtcaacattt ttcaggaaccacttcccaatc 69
RRM1 actaagcaccctgactatgctatcc cttcctcacatcactgaacacttt 88
RRM2 ggctcaagaaacgaggactg tcaggcaagcaaaatcacag 93
CDA tcaaagggtgcaacatagaaaatg cggtccgttcagcacagat 61
β-actin tgagcgcggctacagctt tccttaatgtcacgcacgattt 60
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and CDA mRNA levels in 70 FFPE tissue samples of resected PDAC
using qRT-PCR. The relationship between gemcitabine-based AC and
clinicopathologic characteristics or each mRNA level is summarized in
Tables W2 andW3. The GEM and non-AC groups were composed of
40 and 30 cases, respectively. There was no significant correlation be-
tween gemcitabine-based AC and the clinicopathologic factors or any
of the mRNA levels in PDAC patients. Also, there were no significant
differences in the mRNA levels of any of the genes between the two
groups (Figure W1, A-E ).
Figure 1. Quantitative analyses of mRNA associated with cellular uptake and metabolism of gemcitabine in gemcitabine-resistant cells.
Quantitative analysesofhENT1 (A),dCK (B),RRM1 (C),RRM2 (D), andCDA (E)mRNA ingemcitabine-resistant cell lines (SUIT-2-GR andCapan-
1-GR) and parental cells. SUIT-2-GR cells expressed significantly lower levels of hENT1 and dCK and significantly higher levels of RRM1 and
CDA compared with parental cells. Capan-1-GR cells expressed significantly lower levels of dCK and significantly higher levels of CDA com-
pared with parental cells, although expression levels of CDA were lower than those of SUIT-2 cells.
Table 2. IC50 of Each Cell Line.
Cell Line IC50 (nM) P
Parental Cells Gemcitabine-Resistant Cells
SUIT-2 2.76 ± 0.19 8576.14 ± 156.41 <.01
Capan-1 62.62 ± 5.33 23,520.71 ± 680.72 <.01
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Initially, we investigated independent markers that indicated poor
prognosis in 70 PDACpatients.We obtained two groups for each gene
showing high or low expression, respectively, after normalization to
β-actin expression, using cutoff values calculated by recursive descent
partition analyses [32] of all patients (N = 70; TableW3). In univariate
analyses for OS, the conventional prognostic markers, gemcitabine-
based AC (Figure 2; P = .0017), pN status (P = .049), histologic grade
(P = .0043), residual tumor (P = .0009), and positive vessel inva-
sion (P = .044) reached significance (Table 3), whereas low dCK (P =
.019) and high RRM2 (P = .015) levels normalized to β-actin were
associated with a shorter OS (Table 4). Multivariate analysis for OS
based on theCox proportional hazardmodel was performed on all param-
eters that were found to be significant on univariate analyses (Table 5).
Although OS was significantly dependent on history of gemcitabine-
based AC (P = .0001), histologic grade (P < .0001), and R factor (P =
.0003), the effects of low dCK and high RRM2 levels did not reach
statistical significance. Also, multivariate analysis for DFS (Table W4)
showed that DFS was significantly dependent on the histologic grade
(P = .0033) and R factor (P < .0001).
Next, to determine which parameters are predictive for gemcitabine
sensitivity, we evaluated the correlation between each parameter, in-
cluding gene expression, and DFS in the GEM and non-AC groups.
Univariate survival analyses of the GEM group showed that pN status
(P = .0052), UICC stage (P = .0066), residual tumor (P = .0002), and
positive vessel invasion (P = .018) reached statistical significance for
DFS, whereas low dCK (P = .0067) and high RRM2 (P = .003) levels
normalized to β-actin were associated with a shorter DFS (Table 6).
Low hENT1 (P = .11) and high RRM1 (P = .069) groups tended to
associate with a shorter DFS, although these markers did not reach sta-
tistical significance (Table 6; Figure 3, A, C , E , and G ). In contrast,
there was no significant correlation between these gene expression
levels and DFS in the non-AC group (Figure 3, B,D, F, andH ). Mul-
tivariate analysis of the GEM group (Table 7) showed that DFS was
significantly dependent on the R factor (P = .0055) and RRM2 level
(P = .0055), whereas the effect of low dCK levels did not reach statis-
tical significance.
Similarly, we also evaluated the correlation between each parameter
and OS in the GEM and non-AC groups. Univariate survival analyses
of the GEM group showed that the conventional prognostic markers
pN status (P = .014) and residual tumor (P = .0012) reached statistical
significance for OS (Table 6). Low hENT1 (P = .011) and dCK (P =
.0095) and high RRM1 (P = .041) and RRM2 (P = .030) levels, nor-
malized to β-actin, were associated with a shorter OS (Table 6; Figure 4,
A, C , E , and G ). In contrast, there was no significant correlation be-
tween these gene expression levels and OS in the non-AC group (Fig-
ure 4,B,D, F, andH ).Multivariate analysis of theGEMgroup (Table 8)
showed thatOSwas significantly dependent on pN status (P = .029) and
R factor (P = .0027), whereas altered gene expression did not reach sta-
tistical significance for any gene.
Figure 2. Correlation between gemcitabine-based AC and survival
time. The patients who received gemcitabine-based AC (GEMgroup)
showed a significantly prolongedOS time comparedwith thenon-AC
group (P = .0017). *P < .05.
Table 3. Univariate Survival Analysis of Conventional Prognostic Factors (N = 70).
Characteristics No.
Cases
Median DFS
(Months)
P Median OS
(Months)
P 5-Year
Survival
Rate (%)
Age (years) .95 .89
≥65 36 8 15 18.7
<65 34 8 14.5 24.3
Sex .94 .69
Male 42 8 15 18.9
Female 28 7 16.5 20.8
Gemcitabine-based AC .078 .0017*
Yes 40 10 23 27.8
No 30 7 9 8.3
Radiotherapy .81 .54
Yes 19 8 22 25.3
No 43 8 14.7 9.4
pT category .11 .063
pT1/pT2 4 4 10 0
pT3/pT4 66 8 16.5 21.8
pN category .0064* .049*
pN0 20 28 33 28.9
pN1 50 7 13.7 17.4
UICC stage .022* .29
I 2 12.6 24.2 0
II 64 8 16.5 22.6
III/IV 4 2 12 0
Histologic grade .0036* .0043*
G1/G2 41 14 26 27.8
G3 29 4 12 13.6
Residual tumor category <.0001* .0009*
R0 39 19 24.2 33.2
R1 31 4 12 6.5
Vessel invasion .0083* .044*
Positive 46 6 13.3 15.0
Negative 24 14 24.2 31.8
Neural invasion .68 .56
Positive 57 8 15 20.2
Negative 13 14 19 22.4
*P < .05.
Table 4. Univariate Survival Analysis of mRNA Expression Levels (N = 70).
Characteristics No.
Cases
Median DFS
(Months)
P Median OS
(Months)
P 5-Year
Survival
Rate (%)
hENT1 (cutoff value: 0.5) .13 .45
High 27 12 23 31.8
Low 43 8 14.5 11.6
dCK (cutoff value: 1.25) .028* .019*
High 19 20 30 34.5
Low 51 7 13.7 14.6
CDA (cutoff value: 0.034) .26 .54
High 32 7 14.7 21.2
Low 38 8 22 20.6
RRM1 (cutoff value: 0.032) .15 .094
High 19 4 12 23.7
Low 51 10 19 20.5
RRM2 (cutoff value: 0.017) .047* .015*
High 50 7 13 17.1
Low 20 19 23 30.3
Cutoff values were determined with recursive descent partition analyses of all patients (N = 70).
*P < .05.
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Table 6. Univariate Survival Analysis of Conventional Prognostic Factors and of mRNA Expression
Levels in the GEM Group (n = 40).
Characteristics No.
Cases
Median DFS
(Months)
P Median OS
(Months)
P 5-Year
Survival
Rate (%)
Age (years) .52 .56
≥65 17 8 27 24.5
<65 23 10 23 32.7
Sex .36 .33
Male 26 14 27 29.1
Female 14 6 16.5 21.4
Radiotherapy .20 .085
Yes 9 19 27 41.7
No 27 8 19 12.9
pT category .25 .084
pT1/pT2 1 4 10 0.0
pT3/pT4 39 10 26 28.5
pN category .0052* .014*
pN0 9 23 45 47.4
pN1 31 8 19 21.5
UICC stage .0066* .13
I 0 — — —
II 37 12 23 30.3
III/IV 3 3 12 0
Histologic grade .056 .075
G1/G2 23 19 31 35.3
G3 17 8 16.5 24.2
Residual tumor category .0002* .0012*
R0 26 20 45 46.6
R1 14 5 13.7 0.0
Vessel invasion .018* .054
Positive 26 8 19 21.1
Negative 14 25 45 40.2
Neural invasion .46 .89
Positive 33 10 26 27.3
Negative 7 19 23 28.6
hENT1 (cutoff value: 0.5) .11 .011*
High 14 25 45 49.0
Low 26 8 16.5 11.5
dCK (cutoff value: 1.25) .0067* .0095*
High 13 25 70 50.5
Low 27 8 16.5 13.7
CDA (cutoff value: 0.013) .48 .79
High 26 8 27 28.2
Low 14 12 23 28.6
RRM1 (cutoff value: 0.017) .069 .041*
High 12 8 19 47.6
Low 28 33 31 19.8
RRM2 (cutoff value: 0.027) .003* .03*
High 27 8 16.3 18.8
Low 13 19 3.2 49.4
Cutoff value for each mRNA level was determined for the GEM group (n = 40).
*P < .05.
Table 5. Multivariate OS Analysis (Cox Regression Model) of Conventional Prognostic Factors
and mRNA Expression Levels (N = 70).
Characteristics Relative Risk 95% Confidence Interval P
No AC 3.418 1.832-6.389 .0001*
pN status (pN1) 2.093 0.974-4.892 .059
Histologic grade (G3) 4.322 2.169-8.698 <.0001*
Residual tumor (pR) 3.328 1.746-6.398 .0003*
Positive vessel invasion 1.179 0.601-2.458 .64
Low dCK (<1.25) 0.811 0.411-1.682 .560
High RRM2 (>0.017) 1.106 0.570-2.295 .770
Cutoff values were determined with recursive descent partition analyses of all patients (N = 70).
*P < .05.
Figure 3. Correlation between the expression of each mRNA and
DFS. Low dCK (P= .0067) and high RRM2 (P= .003) levels, normal-
ized to β-actin, were associated with a shorter DFS in the GEM
group (A, C, E, G). In contrast, there was no significant correlation
between these gene expression levels andDFS in the non-AC group
(B, D, F, H). *P < .05.
Table 7. Multivariate DFS Analysis (Cox Regression Model) of Conventional Prognostic Factors
and mRNA Expression Levels in the GEM Group (n = 40).
Characteristics Relative Risk 95% Confidence Interval P
pN status (pN1) 1.678 0.553-7.432 .39
UICC Stage III/IV 7.105 0.915-44.23 .059
Residual tumor (pR1) 3.683 1.474-9.536 .0055*
Positive vessel invasion 1.446 0.610-3.821 .41
Low dCK (<1.25) 2.381 0.891-7.069 .084
High RRM2 (>0.027) 3.780 1.450-11.81 .0055*
Each cutoff value of mRNA expression level was determined with the GEM group (n = 40).
*P < .05.
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Furthermore, we created a combined score, which was calculated
from each gene expression score determined with recursive descent par-
tition analysis of the GEMgroup, and evaluated the correlation between
survival time and this combined score. Each gene expression was scored
as follows: low hENT1, low dCK, high RRM1, and high RRM2, 1; high
hENT1, high dCK, low RRM1, and low RRM2, 2. A combined score
was created: GEM score = hENT1 score × dCK score × RRM1 score ×
RRM2 score. As a result, high GEM score was correlated well with pro-
longedDFS (Figure 5A) andOS (Figure 5B) in GEM group patients. In
univariate analyses of the GEM group, a low GEM score (<2) was asso-
ciated with both of a shorter DFS (P = .0003) and a shorter OS (P <
.0001). In multivariate analyses of the GEM group, DFS (Table 9)
was significantly dependent on UICC stage III/IV (P = .048), R factor
(P = .030), and low GEM score (<2, P = .0081), and OS (Table 10)
was significantly dependent on pN status (P = .0044), R factor (P =
.011), and low GEM score (<2, P = .0002). A low GEM score was an
independent predictive and prognostic factor for poor survival in PDAC
patients receiving gemcitabine-based AC, with a relative risk of 3.515
and 5.677, respectively.
Quantitative Analyses of hENT1, dCK, and RRM2 Expression
in Cells Microdissected from Cytologic Specimens
To apply the prediction of gemcitabine sensitivity, based on gene
expression levels, to a clinical setting, we quantified hENT1, dCK,
Figure 4. Correlationbetween theexpressionof eachmRNAandOS.
Low hENT1 (P = .011), low dCK (P = .0095), high RRM1 (P = .041),
and high RRM2 (P= .030) levels, normalized to β-actin, were associ-
atedwith a shorterOS in theGEMgroup (A, C, E, G). In contrast, there
was no significant correlation between these gene expression levels
and OS in the non-AC group (B, D, F, H). *P < .05.
Table 8. Multivariate OS Analysis (Cox Regression Model) of Conventional Prognostic Factors
and mRNA Expression Levels in the GEM Group (n = 40).
Characteristics Relative Risk 95% Confidence Interval P
pN status (pN1) 4.411 1.146-23.90 .029*
Residual tumor (pR1) 3.574 1.561-8.470 .0027*
Low hENT1 (<0.5) 2.980 0.964-10.86 .20
Low dCK (<1.25) 2.080 0.694-7.551 .058
High RRM1 (>0.017) 2.803 0.998-9.113 .051
High RRM2 (>0.027) 2.357 0.935-6.863 .070
Cutoff value for each mRNA level was determined for the GEM group (n = 40).
*P < .05.
Figure 5. Correlation between GEM score and survival time. DFS
time (A) andOS time (B) after resection of PDAC categorized by com-
binedGEMscore (hENT1 score× dCK score×RRM1 score×RRM2
score) in GEMgroup patients. HighGEMscoreswerewell correlated
with prolonged DFS time (A) and OS time (B). *P < .05.
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RRM1, and RRM2 mRNA levels in cytologic specimens obtained
from 15 patients with PDAC who underwent EUS-FNA cytologic
examination in our institute. Although a few samples contained abun-
dant neoplastic cells, most samples contained a large amount of blood
and inflammatory cells and contained scarce clusters of neoplastic
cells (Figure 6, A and B). Therefore, we quantified mRNA levels from
WCPs and from microdissected neoplastic cells (laser capture micro-
dissection) prepared from these samples and then compared expres-
sion levels between the two preparations. We were unable to detect
clear differences in mRNA levels among the WCP samples; however,
we could distinguish higher and lower expression levels of each gene
among microdissected neoplastic cell samples (Figure 6, C -F ). These
data suggest that quantification of individual gene expression levels
in microdissected neoplastic cells is a potent tool to predict gemcita-
bine sensitivity even when specimens contain abundant contaminat-
ing cells.
Discussion
PDAC remains a major therapeutic challenge. Recent randomized
clinical trials showed a significant clinical benefit of gemcitabine-
based chemotherapy in patients with both resected and unresectable
PDAC [7,33]. Therefore, gemcitabine-based chemotherapy remains
the standard palliative chemotherapy for PDAC. However, there re-
mains a substantial subset of cases in which gemcitabine-based chemo-
therapy is insufficient, suggesting the importance of introducing
individualized chemotherapy into the clinical setting. Individualized
chemotherapy, based on the expression of genes involved in cellular
uptake and metabolism of gemcitabine, will be a potent strategy.
We and other investigators have demonstrated that several altered
gene expression profiles, including those of hENT1, dCK, RRM1, and
RRM2 correlated with the sensitivity to gemcitabine in cancer cell lines
[12,15,20,22]. However, analysis of gene expression in two gemcitabine-
resistant pancreatic cancer cell lines revealed that there were differences
in gene expression between these cancer cell lines. These data suggest
that there are different patterns of gene expression that can develop
gemcitabine resistance, and combined evaluation of several genes
may be required to predict gemcitabine sensitivity.
In the current study, univariate analyses showed that low hENT1,
low dCK, high RRM1, and high RRM2 correlated well with poor out-
come in patients treated with gemcitabine-based AC, although these
altered expression levels did not reach statistical significance in multivar-
iate analysis. Recent clinical studies, including two prospective clinical
trials, revealed that PDAC patients with high hENT1 immunoreactivity
or high hENT1 expression gained significant benefit from gemcitabine-
based AC [13,34,35], and these data are consistent with our results.
However, although Akita et al. [36] and Zheng et al. [37] revealed that
high RRM1 and high excision repair cross-complementation group 1–
expressing patients with PDAC or NSCLC had prolonged survival re-
gardless of AC, Nakahira et al. [20] and Akita et al. [36] also demon-
strated that only patients with low RRM1 derive significant benefit from
gemcitabine on disease recurrence. Therefore, RRM1 expression may
contribute to gemcitabine resistance in PDAC. Moreover, although
Sebastiani et al. [38] demonstrated that PDAC patients with high
dCK expression had prolonged survival regardless of AC and con-
cluded that genetic alterations of dCK are not a common mechanism
of resistance to gemcitabine, previous in vitro studies [15,16,22] sup-
port our results showing that high dCK and low RRM2 expressions
are correlated with prolonged survival time in PDAC patients who
received gemcitabine-based AC. Therefore, to introduce individual-
ized AC into the clinical setting, based on gene expression profiles,
the expression levels of several genes will need to be determined, and
combined evaluation of these results may be needed. For this reason,
we evaluated a simplified score, the GEM score, and found that a low
GEM score was predictive for reduced DFS and prognostic for re-
duced survival in resected PDAC treated with gemcitabine-based
AC. However, to evaluate the usefulness of this score, further studies,
incorporating larger patient numbers, are required.
In contrast, we found that there was no evident correlation between
CDA expression levels and survival time. Recently, a single-nucleotide
polymorphism in theCDA gene, which was analyzed using the periph-
eral blood of cancer patients, was reported to influence the pharmaco-
kinetics and toxicity of gemcitabine [39]. Bengala et al. [40] also
demonstrated that high CDA expression and CDA activity levels in
peripheral blood mononuclear cells were correlated with shorter sur-
vival in gemcitabine-treated patients with advanced pancreatic carci-
noma. These data suggest that simple quantification of CDA mRNA
in PDAC tissues is not helpful in predicting sensitivity of gemcita-
bine treatment.
Only 10% to 20% of patients with PDAC are candidates for cu-
rative resection [3]; therefore, the remaining 80% to 90% of patients
with unresectable advanced PDAC need cytopathologic assessment
of EUS-FNA specimens, or pancreatic juice specimens, to predict
their sensitivity to chemotherapeutic agents for individualized che-
motherapy. The present analysis of mRNA is quantitative (even con-
sidering the small amount of specimen available, including cytologic
specimens). In addition, the present results revealed that quantifica-
tion of mRNA in neoplastic cells microdissected from cytologic sam-
ples was more useful to distinguish between samples with higher and
lower gene expression levels compared with the analysis of WCP
samples. The reliability of tests based on tissue or cell extracts is often
crucially dependent on the relative abundance of the target cell pop-
ulation, and sampling errors or a large number of “contaminating
cells” can lead to false-negative results [26]. hENT1 and dCK mRNA
were reported to be expressed in human T lymphocytes and mono-
cytes [41,42], and RRM1 and RRM2 are essential for DNA synthesis
in somatic cells. For these reasons, quantification of gene expression
Table 10. Multivariate OS Analysis (Cox Regression Model) of Conventional Prognostic Factors
and GEM Score in the GEM Group (n = 40).
Characteristics Relative Risk 95% Confidence Interval P
pN status (pN1) 4.907 1.560-22.48 .0044*
Residual tumor (pR1) 2.874 1.275-6.651 .011*
GEM score < 2 5.677 2.237-16.17 .0002*
Cutoff value for each mRNA level was determined for the GEM group (n = 40).
*P < .05.
Table 9. Multivariate DFS Analysis (Cox Regression Model) of Conventional Prognostic Factors
and GEM Score in the GEM Group (n = 40).
Characteristics Relative Risk 95% Confidence Interval P
pN status (pN1) 3.111 0.968-14.10 .057
UICC Stage III/IV 7.935 1.026-49.18 .048*
Residual tumor (pR1) 2.668 1.099-6.480 .030*
Positive vessel invasion 1.202 0.488-3.310 .70
GEM score < 2 3.515 1.376-9.963 .0081*
Each cutoff value of mRNA expression level was determined with GEM group (n = 40).
*P < .05.
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in cells microdissected from EUS-FNA cytologic specimens is likely
to be useful for predicting gemcitabine sensitivity in patients with
PDAC, although further investigations are needed before this ap-
proach can be introduced into the clinical setting.
In conclusion, we demonstrated that quantitative analysis of
hENT1, dCK, RRM1, and RRM2 mRNA using FFPE tissue samples
and evaluation of a combined GEM score were useful in predicting
the sensitivity to gemcitabine-based AC in patients with PDAC. In
addition, quantitative analysis of these genes in neoplastic cells mi-
crodissected from EUS-FNA specimens was useful in determining
the treatment for patients with PDAC even when the tumor is un-
resectable. Quantitative analyses of genes related to cellular uptake
and metabolism of cytotoxic agents can be a potent tool to perform
individualized chemotherapy.
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Table W2. Relationship between Gemcitabine-Based AC and Various Clinicopathologic Factors
(N = 70).
Characteristics Gemcitabine-Based AC P
GEM Group (n = 40) Non-GEM Group (n = 30)
Age (years), n (%) .097
≥65 17 (42.5) 19 (63.3)
<65 23 (57.5) 11 (36.7)
Sex, n (%) .338
Male 26 (65.0) 16 (53.3)
Female 14 (35.0) 14 (46.7)
Radiotherapy, n (%) .278
Yes 9 (22.5) 10 (33.3)
No 31 (77.5) 20 (66.7)
pT category, n (%) .307
pT1/pT2 1 (2.5) 3 (10.0)
pT3/pT4 39 (97.5) 27 (90.0)
pN category, n (%) .285
pN0 9 (22.5) 11 (36.7)
pN1 31 (77.5) 19 (63.3)
UICC stage, n (%) .202
I 0 (0) 2 (6.7)
II 37 (92.5) 27 (90.0)
III/IV 3 (7.5) 1 (3.3)
Histologic grade, n (%) .974
G1 8 (20.0) 6 (20.0)
G2 15 (37.5) 12 (40.0)
G3 17 (42.5) 12 (40.0)
Residual tumor category, n (%) .091
R0 26 (65.0) 13 (43.3)
R1 14 (35.0) 17 (56.7)
Vessel invasion 1.000
Positive 26 (65.0) 20 (66.7)
Negative 14 (35.0) 10 (33.3)
Neural invasion, n (%) 1.000
Positive 33 (82.5) 24 (80.0)
Negative 7 (17.5) 6 (20.0)
Table W1. Clinicopathologic Characteristics of the Patients (N = 70).
Age, median (range), years 65 (36-86)
Sex, male/female, n (%) 42 (60.0)/28 (40.0)
Gemcitabine-based AC, n (%)
Yes 40 (57.1)
No 30 (42.9)
Histologic diagnosis, n (%)
Adenocarcinoma 66 (94.3)
Adenosquamous carcinoma 4 (5.7)
pT category, n (%)
pT1 1 (1.4)
pT2 3 (4.3)
pT3 65 (92.9)
pT4 1 (1.4)
pN category, n (%)
pN0 20 (28.6)
pN1 50 (71.4)
UICC stage, n (%)
I 2 (2.9)
II 64 (91.4)
III 1 (1.4)
IV 3 (4.3)
Histologic grade, n (%)
G1 14 (20.0)
G2 27 (38.6)
G3 29 (41.4)
Residual tumor category, n (%)
R0 39 (55.7)
R1 31 (44.3)
Vessel invasion, n (%)
Positive 46 (65.7)
Negative 24 (34.3)
Neural invasion, n (%)
Positive 57 (81.4)
Negative 13 (18.6)
Table W3. Relationship between Gemcitabine-Based AC and the Expression Level of Each mRNA.
Characteristics Gemcitabine-Based AC P
GEM Group (n = 40) Non-GEM Group (n = 30)
hENT1 (cutoff value: 0.5*), n (%) .62
High 14 (35.0) 13 (43.3)
Low 26 (65.0) 17 (56.7)
dCK (cutoff value: 1.25*), n (%) .29
High 13 (32.5) 6 (20.0)
Low 27 (67.6) 24 (80.0)
CDA (cutoff value: 0.034†), n (%) .33
High 16 (40.0) 16 (53.3)
Low 24 (60.0) 14 (46.7)
CDA (cutoff value: 0.013‡), n (%) .34
High 26 (65.0) 16 (53.3)
Low 14 (35.0) 14 (46.7)
RRM1 (cutoff value: 0.032†), n (%) .41
High 9 (22.5) 10 (33.3)
Low 31 (77.5) 20 (66.7)
RRM1 (cutoff value: 0.017‡), n (%) .08
High 28 (70.0) 14 (46.7)
Low 12 (30.0) 16 (53.3)
RRM2 (cutoff value: 0.017†), n (%) .80
High 28 (70.0) 22 (73.3)
Low 12 (30.0) 8 (26.7)
RRM2 (cutoff value: 0.027‡), n (%) .62
High 27 (67.5) 18 (60.0)
Low 13 (32.5) 12 (40.0)
*Cutoff values were the same in recursive descent partition analyses of all patients (N = 70) and
GEM group (n = 40).
†Cutoff values were determined with recursive descent partition analyses of all patients (N = 70).
‡Cutoff values were determined with recursive descent partition analyses of the GEM group (n = 40).
Table W4.Multivariate DFS Analysis (Cox Regression Model) of Conventional Prognostic Factors
and mRNA Levels (N = 70).
Characteristics Relative Risk 95% Confidence Interval P
pN status (pN1) 1.987 0.899-4.936 .092
UICC Stage — — .066
Histologic grade (G3) 2.898 1.427-5.977 .0033*
Residual tumor (pR) 5.741 2.689-12.70 <.0001*
Positive vessel invasion 1.446 0.702-3.218 .33
Low dCK (<1.25) 0.884 0.408-2.023 .76
High RRM2 (>0.017) 1.538 0.754-3.410 .24
Cutoff values were determined with recursive descent partition analyses of all patients (N = 70).
Relative risk of UICC stage was not shown because of two parameters.
*P < .05.
Figure W1. Quantitative analyses ofmRNA associatedwith cellular uptake andme-
tabolism of gemcitabine in FFPE PDAC tissues. Quantitative analyses of hENT1 (A),
dCK (B), RRM1 (C), RRM2 (D), and CDA (E) mRNA in FFPE PDAC tissues (N = 70).
There was no significant difference in mRNA levels of any gene between the GEM
and non-AC groups (A-E).
